Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

AbbVie has agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid pain treatment candidates. | AbbVie has agreed to pay $30 million upfront to Chinese ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...